Calf diarrhea caused by enterotoxigenic E. coli (ETEC) poses an enormous economic challenge in the cattle industry. Fimbriae and enterotoxin are crucial virulence factors and vaccine targets of ETEC. Since these proteins have complicated components with large molecular masses, the development of vaccines by directly expressing these potential targets is cumbersome Therefore, this study aimed to develop a multiepitope fusion antigen designated as MEFA by integrating major epitopes of FanC and Fim41a subunits and a toxoid epitope of STa into the F17G framework. The 3D modeling predicted that the MEFA protein displayed the epitopes from these four antigens on its surface, demonstrating the desired structural characteristics. Then, the MEFA protein was subsequently expressed and purified for mouse immunization. Following that, our homemade ELISA showed that the mouse antiserum had a consistent increase in polyclonal antibody levels with the highest titer of 1:2¹⁷ to MEFA. Furthermore, the western blot assay demonstrated that this anti-MEFA serum could react with all four antigens. Further, this antiserum exhibited inhibition on ETEC adhesion to HCT-8 cells with inhibitory rates of 92.8%, 84.3%, and 87.9% against F17⁺, F5⁺, and F41⁺ ETEC strains, respectively. Additionally, the stimulatory effect of STa toxin on HCT-8 cells was decreased by approximately 75.3% by anti-MEFA serum. This study demonstrates that the MEFA protein would be an antigen candidate for novel subunit vaccines for preventing ETEC-induced diarrhea in cattle.

Lumpy skin disease (LSD) is an important infectious disease caused by lumpy skin disease virus (LSDV) in bovine. LSDV, sheep pox virus (SPPV), and goat pox virus (GTPV) from the same genus Capripoxvirus (CaPV) of the Poxviridae family exhibit a nucleotide sequence similarity of up to 97%. Therefore, attenuated vaccines of GTPV and SPPV are often used to vaccinate cattle against LSD. However, available serological testing methods cannot accurately differentiate cattle vaccinated with GTPV from those infected with LSDV, posing a significant risk for disease spread. In this study, we developed a synthesized gene unique to LSDV as a differential antigen to detect serum antibodies specific to LSDV and differentiate naturally infected from vaccinated animals (DIVA). We used it for an in‐house indirect enzyme‐linked immunosorbent assay (iELISA), and no cross‐reaction with positive sera for bovine viral diarrhea virus (BVDV), infectious bovine rhinotracheitis virus (IBRV), Mycobacterium bovis (M. Tb), Pasteurella multocida (P. multocida), and Mycoplasma bovis (M. bovis). The cut‐off value (S/P%) was 30% for in‐house iELISA. The corresponding diagnostic specificity was 100% (95% CI: 88.43–100), and the diagnostic sensitivity was 93.3% (95% CI: 77.93–99.18). The intra‐assay coefficient of variation (CV) ranged from 1.08% to 4.11%, and the interassay CV was 0.00%–8.90%. Furthermore, 200 clinical serum samples were examined, in the vaccinated herd, there were no positive samples (0/141) indicating the strong differentiation ability of this method. On the other hand, in the infected herds, the overall positivity was 33.90% (20/59) (95% CI: 22.08–47.39). In summary, a valuable synthesized protein unique to LSDV was developed and showed a promising application in an iELISA with high specificity and sensitivity in differentiating cattle infected with LSDV from those vaccinated with GTPV.

The global spread of lumpy skin disease (LSD), a devastating cattle disease caused by the lumpy skin disease virus (LSDV), is hampered by the lack of a practical small animal model for vaccine evaluation. Here, we established a mouse model by challenging C57BL/6 mice with goatpox virus (GTPV), a close relative of LSDV. Intranasal inoculation with a high dose (10^4.5 TCID₅₀) of GTPV induced robust infection characterized by weight loss, fever, high viral loads in the lungs and livers, and significant pulmonary pathology including immune cell infiltration and alveolar wall thickening. Infected mice mounted potent humoral immunity, with rapid IgM and sustained IgG and GTPV-specific binding antibody responses. The infection also elicited a dynamic cellular immune response, marked by biphasic IFN-γ production and dose-dependent increases in IL-17A and TNF-α. This GTPV-based murine model effectively recapitulates critical aspects of LSDV pathogenesis and immunity, providing a valuable and accessible tool for the accelerated development and preclinical assessment of novel LSDV vaccines.